1. **FDA panel backs Amgen copy of AbbVie arthritis drug Humira** – Reuters
   Amgen Inc's cheaper version of AbbVie's top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday.

   The panel voted 26-0 that the drug, ABP 501, which was studied in rheumatoid arthritis and plaque psoriasis, was similar in safety and effectiveness to the original. AbbVie is trying to block Amgen's drug from reaching the market. It claims it has patents in place to protect Humira, the world's biggest-selling drug, in the United States until at least 2022.

2. **Government assures action on issues raised by medical devices industry: India Inc** – The Economic Times
   The government has assured an "early action" to resolve issues related to regulatory and fiscal matters raised by the medical devices industry, India Inc said today.

   It has also assured that new Medical Device Rules would be notified at the earliest, Ficci said in a statement.

   The issues were deliberated upon during a meeting convened by the Prime Minister's Office yesterday.

3. **Suven Life gets patents for neuro-degenerative drug** – The Economic Times
   Drug firm Suven Life SciencesBSE 0.61 % has been granted a patent each by India and South Africa for a drug used in treatment of neuro-degenerative diseases.

   In a BSE filing today, Suven Life said it has been granted "one product patent from India and one product patent from South Africa corresponding to the New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases".

4. **Indian companies gearing up to solve the biosimilars puzzle** – Business Standard
   In a commercial feature, Rakesh Rao talks about the Indian companies – such as Biocon, Dr Reddy's, Zydus Cadila, Wockhardt, Intas, etc – are already active in biosimilar markets in India and other emerging markets. Dr Reddy's Laboratories Ltd, the first Indian firm to rollout a
biosimilar, has seen its biologics business grow multiple-fold since the launch of Reditux (rituximab) in 2007 and its products are currently being sold in over 10 emerging markets.

5. **AMRI completes acquisition of Italian API maker Euticals** – Business Standard
   The commercial feature on Albany Molecular Research Inc (AMRI) talks about how the acquisition positions AMRI as one of the largest independent developers and suppliers of active pharmaceutical ingredients (APIs) to the pharmaceutical industry in Europe. AMRI has completed the acquisition of Prime European Therapeuticals SpA, also known as Euticals, a privately-held company headquartered in Lodi, Italy, specialising in custom synthesis and the manufacture of active pharmaceutical ingredients (APIs). This completes the transaction initially announced on May 5, 2016.

6. **Tackling hurdles to healthcare for all** – Mint
   At Mint’s Healthcare event held on 17 June in Mumbai, Dr A. Velumani, chairman and managing director, Thyrocare Technologies; Dr Dileep Mavalankar, director, Indian Institute of Public Health Gandhinagar; Meeta Rajivlochan, principal secretary (reforms), finance department, government of Maharashtra; and Shubhra Mittal, policy and training manager, J-PAL South Asia, Institute for Financial Management and Research, participated in a panel discussion on Healthcare for All: Bridging the gaps.

7. **UN ramps-up HIV, hepatitis C fight, inks pact with Aurobindo Pharma, Emcure, Lupin, others** – The Financial Express
   The Medicines Patent Pool (MPP), a United Nations-backed public health organisation working to increase access to HIV, viral hepatitis-C and tuberculosis treatments in low and middle-income countries, has signed manufacturing licences with six Indian pharmaceutical companies to produce generic versions of anti-retrovirals and hepatitis-C anti-viral.

   The companies include Aurobindo Pharma, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila, besides a Chinese company Desano, for a total of nine sub-licensing agreements.

8. **Sun Pharma rolls out anti-cancer drug bag in Europe** – The Hindu
   Sun Pharmaceutical Industries Ltd has announced the roll-out of Gemcitabine InfuSMART, the world’s first licensed, ready-to-administer bag for oncology treatment in Europe.

   This is part of the company’s plans to build a differentiating presence in the global oncology therapy market. Sun Pharma is the world’s fifth largest specialty generic pharmaceutical company and India’s biggest. The company said Gemcitabine InfuSMART has been developed by its R&D team in India. “InfuSMART is a technology in which oncology products are developed in a Ready-To-Administer (RTA) bag.

9. **FDI in Brownfield pharma projects may help to increase exports, supportive to SSIs: TN IDMA** – Pharmabiz.com
   Fully agreeing with the point that 100 per cent FDI in Greenfield pharmaceutical projects in India is dangerous to domestic pharma sector, the chairman of the Tamil Nadu IDMA, J Jayaseelan said that FDI is advantageous and supportive for companies engaged in pharmaceutical exports.

   “As far as export is concerned FDI is very much beneficial and gainful. Foreign investment in the Brownfield projects through automatic route will definitely boost the export business. But if it is for domestic marketing purpose, we have to be careful”, he said.

   According to him, in the last ten years an investment of Rs.70,000 crore was made into Indian pharma industry by foreign players. Most of the investing companies are marketing companies
from US and European countries. He said FDI flow is continuing to India through automatic route till October 2011.

10. **Research on TB: A National Priority** – Indiainfoline.com
The Central TB division (CTD), Ministry of Health & Family Welfare, the North Maharashtra University (NMU) together with The International Union against Tuberculosis and Lung Disease (The Union) and United States Agency for International Development (USAID) organized a research and academia conclave in the city. The discussion focussed on the need for more students to actively pursue scientific research in the quest for innovative and more effective tuberculosis interventions. The dimensions of this research will encompass various fields such as social sciences, economics, humanities and engineering.